ArticleDiscover oncology2026
Pan-cancer analysis reveals DDIAS as a potential diagnostic biomarker, prognostic indicator, and tumor-immune correlate.
Article in Discover oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
backgroundPan-cancer gene analysis has advanced our understanding of shared oncogenic mechanisms, aiding early diagnosis, prognosis, and targeted therapies. DDIAS (DNA Damage Induced Apoptosis Suppressor) has garnered attention for its tumor-specific expression and prognostic value, yet its diagnostic and therapeutic potential remains underexplored.
methodsWe analyzed DDIAS expression across 33 cancer types in The Cancer Genome Atlas (TCGA). Tumor–normal differential expression was assessed using TCGA normal/adjacent normal tissues where available, including within-patient paired tumor–adjacent comparisons. Diagnostic performance was evaluated by ROC/AUC using TCGA in-cohort controls and further validated in independent GEO cohorts. Prognostic associations (OS/DSS/PFI) were examined with Kaplan–Meier and Cox models, and multivariable Cox regression was performed to account for key clinical covariates when available. Associations with tumor–immune features (immune cell infiltration estimates, checkpoint/cytokine genes), mutations, TMB/MSI, and promoter methylation were also investigated.
resultsDDIAS was significantly upregulated in multiple tumor types and showed strong diagnostic discrimination in several cancers. Higher DDIAS expression was associated with adverse survival outcomes in select entities. DDIAS expression also correlated with tumor–immune features, including immune cell infiltration and immune checkpoint gene expression.
conclusionsThese pan-cancer findings support DDIAS as a potential diagnostic and prognostic marker and suggest associations with tumor–immune modulation. Further mechanistic and experimental studies are warranted to establish causality and therapeutic relevance.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.